RxDoctor Payments Data

Patricia Daly, MD

Psychiatry · Hartford, VTNPI 1578583142

Payments from drug & device makers

No general payments reported

No drug or device maker reported general payments to this provider for 2019–2025. That is a common and unremarkable result.

$424,337in research payments, 2019–2025

Across 88 payments — averaging $4822.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Otsuka Pharmaceutical Development & Commercialization, Inc.$209K
  • Alkermes, Inc.$112K
  • Sunovion Pharmaceuticals Inc.$58K
  • Sage Therapeutics, LLC$22K
  • Avanir Pharmaceuticals, Inc.$12K
  • Livanova USA, Inc.$11K

How this compares

$0 in reported general payments places this provider in the 70th percentile of 96 psychiatry providers in Vermont.

See all psychiatry providers in Vermont

Medicare billing

Part B allowed, 2024
$33,067
Medicare patients
56
Services billed
301

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gabapentin13$354
Lorazepam11$93

Paid to pharmacies, not to this prescriber.

Other psychiatry in Hartford

See the full list for Vermont

Where these figures come from

Is this you, or does something look wrong? →